Atracurium

Introduction

Atracurium is an intermediate-acting, non-depolarizing neuromuscular blocking agent (NMBA) belonging to the benzylisoquinolinium class. It’s prized for its unique metabolism via Hofmann elimination, making it particularly useful in patients with organ dysfunction. It provides reliable muscle relaxation for intubation and surgery, with predictable recovery characteristics.

Chemistry

  • Class: Benzylisoquinolinium compound.Atracurium Chemical Structure
  • Structure: Composed of two quaternary ammonium groups linked by a chain. It’s a mixture of 10 stereoisomers (including the more potent cisatracurium isomer).
  • Key Feature: Contains ester groups susceptible to spontaneous breakdown (Hofmann elimination) and hydrolysis by plasma esterases.

Formulation

  • Presentation: Clear, colorless solution.
  • Concentration: Typically 10 mg/mL or 50 mg/5 mL vials.
  • pH: Acidic (approximately 3.25) – Important: Must be stored refrigerated (2-8°C). Can be stored at room temperature for up to 21 days, but potency decreases faster. Do not freeze.
  • Compatibility: Compatible with common IV solutions (e.g., D5W, NS, LR). Incompatible with alkaline solutions (e.g., thiopental, sodium bicarbonate) – precipitates may form.

Pharmacokinetics

  • Onset: Moderate (2-3 minutes for intubating conditions).
  • Duration of Action: Intermediate (20-35 minutes for intubating dose).
  • Metabolism: Unique Dual Pathway:
    • Hofmann Elimination (Primary): Spontaneous, non-enzymatic, temperature- and pH-dependent chemical breakdown in plasma and tissues. Independent of liver or kidney function. Produces laudanosine and a monoquaternary acrylate metabolite.
    • Ester Hydrolysis (Minor): Catalyzed by nonspecific plasma esterases (not pseudocholinesterase).
  • Elimination: Metabolites (primarily laudanosine) are eliminated renally.
  • Clearance: Rapid, primarily due to Hofmann elimination.
  • Volume of Distribution: Moderate.
  • Key Clinical Implication: Duration is largely unaffected by renal or hepatic failure. No cumulative effect with repeated doses or infusions.

Pharmacodynamics

  • Mechanism: Competitive antagonist at nicotinic acetylcholine receptors (nAChRs) on the post-junctional membrane of the neuromuscular junction (NMJ). Prevents acetylcholine binding and depolarization.
  • Potency: Moderate (ED95 ~0.25 mg/kg).
  • Histamine Release: Significant and dose-dependent. Rapid IV bolus (>0.5 mg/kg) can cause:
    • Cutaneous flushing
    • Hypotension (due to vasodilation)
    • Tachycardia (reflex or direct)
    • Bronchospasm (rare, but risk in reactive airways)
  • Autonomic Effects: Minimal direct cardiovascular effects at standard doses (histamine release is the main cause of hemodynamic changes). No ganglionic blockade or vagolytic activity.
  • Metabolite Effects: Laudanosine: Crosses BBB. At very high concentrations (prolonged infusions in ICU, renal failure), it may cause CNS excitation (tremors, seizures). Rarely clinically significant at standard anesthetic doses/durations.

Uses

  1. Facilitation of Endotracheal Intubation: Provides good conditions within 2-3 minutes.
  2. Maintenance of Skeletal Muscle Relaxation During Surgery: Especially useful for:
    • Procedures of intermediate duration.
    • Patients with significant renal impairment.
    • Patients with significant hepatic impairment.
    • Patients where prolonged paralysis is anticipated (infusions).
    • Cases requiring an “awake test” (e.g., scoliosis surgery, cerebral aneurysm clipping) due to its predictable, non-cumulative recovery.
  3. Facilitation of Mechanical Ventilation: In ICU settings (caution with prolonged infusions).

Dosage

  • Intubating Dose: 0.4 – 0.5 mg/kg IV (provides ~25-40 min relaxation).
  • Maintenance Dose: 0.1 – 0.2 mg/kg IV as needed (typically every 15-25 min).
  • Continuous Infusion: Initial rate 5-10 µg/kg/min, titrated to effect (usually 4-12 µg/kg/min). Monitor neuromuscular function!
  • Pediatric Dose: Similar mg/kg dosing as adults (infants may be slightly more sensitive).

Contraindications

  • Absolute:
    • Known hypersensitivity to atracurium or other benzylisoquinolinium NMBAs (e.g., cisatracurium, mivacurium).
  • Relative:
    • History of severe anaphylaxis to any NMBA.
    • Conditions predisposing to histamine release effects: Severe asthma, unstable cardiovascular disease (use with extreme caution, slow IV push, consider alternatives).
    • Myasthenia Gravis & Myasthenic Syndromes: Markedly increased sensitivity; requires significant dose reduction and intense monitoring.
    • Neuromuscular Diseases: Use with caution (altered response).

Special Considerations & Pearls for Trainees

  • Histamine Release Mitigation: ALWAYS inject slowly (over 30-60 seconds), especially for intubating doses. Consider pre-treatment with H1/H2 blockers (e.g., diphenhydramine + famotidine) or IV lidocaine in high-risk patients. Avoid rapid bolus.
  • Hofmann Elimination is Key: This is its superpower. Duration is predictable regardless of liver/kidney function. Ideal for organ failure cases. Remember it’s temperature/pH dependent (prolonged in hypothermia/acidosis).
  • Laudanosine: Be aware it exists, but don’t panic. Seizures are extremely rare at standard anesthetic doses/durations. Monitor patients on prolonged ICU infusions (especially with renal failure) for CNS excitation.
  • Reversal: Always reverse with Acetylcholinesterase Inhibitors (Neostigmine 0.04-0.07 mg/kg + Glycopyrrolate 0.004-0.01 mg/kg). Sugammadex is NOT effective for atracurium reversal (only for steroidal NMBAs like rocuronium/vecuronium).
  • Monitoring: Quantitative Neuromuscular Monitoring is MANDATORY. Use a peripheral nerve stimulator (e.g., TOF ratio at the adductor pollicis). Goal for Extubation: TOF ratio ≥ 0.9. Never rely on clinical signs alone.
  • Infusion Use: Excellent for prolonged cases due to lack of cumulative effect. Titrate carefully using train-of-four monitoring. Avoid in ICU unless absolutely necessary and with strict monitoring protocols.
  • Comparison to Cis-atracurium: Cisatracurium (one of atracurium’s isomers) is more potent (lower ED95), has less histamine release, and produces less laudanosine. It’s often preferred over atracurium for hemodynamic stability but is more expensive.
  • Acid-Base Status: Hofmann elimination is slowed in acidosis (pH < 7.2), potentially prolonging duration. Alkalosis (pH > 7.6) may accelerate it.
  • Temperature: Hypothermia significantly slows Hofmann elimination, prolonging duration. Maintain normothermia.
  • Drug Interactions: Potentiated by volatile anesthetics (esp. enflurane, isoflurane, sevoflurane), aminoglycoside antibiotics, magnesium, lithium, local anesthetics, calcium channel blockers. Antagonized by acetylcholinesterase inhibitors.

Key Takeaways for Trainees

  1. Hofmann Elimination = Organ Independence: Your go-to NMBA for renal/hepatic failure.
  2. Histamine Release = Slow IV Push: Always inject slowly (30-60 sec) to minimize hypotension/flushing.
  3. Reversal = Neostigmine/Glycopyrrolate: Sugammadex doesn’t work.
  4. Monitor Quantitatively: TOF ratio ≥ 0.9 before extubation is non-negotiable.
  5. No Cumulation: Safe for repeated doses and infusions in long cases.

Atracurium remains a valuable and reliable NMBA in the anesthesia arsenal, particularly when organ function is compromised or predictable, non-cumulative recovery is desired. Understanding its unique metabolism and managing its histamine release potential are essential for safe and effective use

Comments are closed.